Phase Ii Biotransformation
Phase Ii Biotransformation - Related Videos
01:16
Drug Biotransformation: Overview
0 Views •
2023
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
01:28
Drug Biotransformation: Overview
0 Views •
2025
Biotransformation, also known as drug metabolism, is a vital physiological process that chemically alters drugs, facilitating their elimination from the body and terminating their action. This process involves two main phases: phase I and phase II reactions. Phase I reactions, including oxidation, reduction, and hydrolysis, introduce or unmask polar functional groups on the drug molecule, thereby increasing its water solubility. By enhancing water solubility, the drug becomes more hydrophilic...
01:19
Factors Affecting Drug Biotransformation: Biological
0 Views •
2025
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity. Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects. Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
02:39
Phase Diagrams
0 Views •
2020
A phase diagram combines plots of pressure versus temperature for the liquid-gas, solid-liquid, and solid-gas phase-transition equilibria of a substance. These diagrams indicate the physical states that exist under specific conditions of pressure and temperature and also provide the pressure dependence of the phase-transition temperatures (melting points, sublimation points, boiling points). Regions or areas labeled solid, liquid, and gas represent single phases, while lines or curves represent...
01:21
Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs
0 Views •
2025
A drug's physicochemical properties fundamentally influence its metabolism. For instance, a drug's molecular size and shape critically determine its interaction with enzymes and transporters — larger drugs may face difficulty reaching enzyme active sites, altering their metabolic pathways. The pKa of a drug, which establishes its ionization state, can impact its solubility and absorption, thereby influencing metabolism. The drug's acidity or basicity is essential in determining the metabolic...
FAQs
Conjugating enzymes transfer endogenous groups to functional sites on a drug or xenobiotic. The available site and attached group, such as glucuronic acid, sulfate, acetyl, methyl, or glutathione, influence the resulting metabolite’s chemical properties. This modification commonly increases polarity and aqueous solubility, which can favor elimination, although the clinical activity of the metabolite must still be considered.
The attached chemical group changes the parent compound’s structure and biological behavior, but the overview does not imply that every conjugated metabolite loses activity. Some products may remain pharmacologically active, whereas others may be inactive. Consequently, evaluating this pathway requires attention to both the drug’s elimination rate and the properties of metabolites formed during conjugation.
Conjugation capacity varies with genetic differences, disease, age, and coadministered medicines. These factors can alter how efficiently a drug is modified, changing its half-life and the amount or type of metabolite formed. Such variation helps explain why the same medicine may produce different responses or toxicity risks among patients and why dosing may need individualization.
Coadministered medicines can alter conjugation capacity, which may change the metabolism and elimination of another drug. The resulting effect can involve a different half-life, altered metabolite formation, or changes in drug response and toxicity. Clinical interpretation therefore considers the complete medication regimen rather than treating a conjugation pathway as an isolated property of one drug.
Differences in conjugation capacity can change how long a drug remains in the body and whether active or inactive metabolites accumulate. These changes may influence therapeutic response as well as toxicity. In clinical pharmacology, recognizing that variability helps connect metabolic differences with observed patient outcomes and supports decisions about individualized dosing when standard exposure may not apply.
Individualized dosing becomes relevant when genetic variation, disease, age, or other medicines changes a patient’s ability to conjugate drugs. Reduced or altered capacity may affect half-life, metabolite formation, response, or toxicity, while differences in capacity can produce the opposite pattern. Considering these variables helps clinicians relate metabolic behavior to the patient’s expected drug exposure and response.